Table 1. Clinical features of subjects.
| Control | COPD | P value | |
|---|---|---|---|
| Number of subjects | 19 | 18 | |
| Age (Year) | 53.8 ± 4.9 | 61.3 ± 1.6 | NS |
| Gender (M/F) | 10/9 | 11/7 | NS |
| Smoking history (Non-smoker/Smoker/NA) | 7/8/4 | 0/18/0 | < 0.001 |
| Smoking (pack-years) | 24.2 ± 13.1 | 45.5 ± 4.9 | < 0.05 |
| GOLD stage (I/II/III/IV) | 0/0/0/0 | 0/2/10/6 | |
| FVC * (% of predicted value) | 104.2 ± 7.1 | 76.0 ± 5.5 | < 0.01 |
| FEV1 † (% of predicted value) | 101.0 ± 8.1 | 33.5 ± 3.9 | < 0.0001 |
| DLco ‡ (% of predicted value) | 87.5 ± 9.8 | 38.2 ± 3.8 | < 0.0001 |
| mPAP § (mmHg) | NA | 25.8 ± 3.2 | |
| 6MWD a (m) | NA | 270.0 ± 25.3 |
Definition of Abbreviations: COPD; chronic obstructive pulmonary disease, NS; not significant, NA; data not available, GOLD; Global Initiative for Chronic Obstructive Lung Disease, DLco; diffusion capacity for carbon monoxide, mPAP; mean pulmonary arterial pressure, 6MWD; 6-minute walk distance. Values are mean ± SEM, except for a number of subjects, gender, smoking history and GOLD stage (number).
* FVC % predicted values are from 6 subjects of control and 18 subjects of COPD.
† FEV1% predicted values are from 6 subjects of control and 18 subjects of COPD.
‡ DLco % predicted values are from 5 subjects of control and 14 subjects of COPD.
§ mPAP values are from 12 subjects of COPD.
a 6MWD values are from 12 subjects of COPD.